Current evidence on the management of re-recurrent rectal cancer: a systematic review - Takeaways - MDSpire

Current evidence on the management of re-recurrent rectal cancer: a systematic review

  • By

  • Georgios Giannos

  • Panagiotis Theodoropoulos

  • Maximos Frountzas

  • Sheng Qiu

  • Maria Katsigeorgis

  • Sophia Y. Chen

  • Shahnawaz Rasheed

  • Paris Tekkis

  • Bashar Safar

  • Christos Kontovounisios

  • July 15, 2026

Share

  • 1

    Re-recurrent rectal cancer (RRRC) is a complex disease requiring specialized management following curative-intent treatment of recurrent rectal cancer.

  • 2

    This systematic review included three retrospective cohort studies with a total of 169 patients undergoing curative-intent surgery for RRRC.

  • 3

    Neoadjuvant therapy was administered to 20–92% of patients, with pelvic exenteration frequently required in RRRC management.

  • 4

    R0 resection rates in the studies ranged from 33% to 62%, with margin status being a key prognostic determinant of oncological outcomes.

  • 5

    The review highlights the need for standardized, consensus-based recommendations due to variability in perioperative management and outcomes.

Original Source(s)

Current evidence on the management of re-recurrent rectal cancer: a systematic review

  • by Georgios Giannos, Panagiotis Theodoropoulos, Maximos Frountzas, Sheng Qiu, Maria Katsigeorgis, Sophia Y. Chen, Shahnawaz Rasheed, Paris Tekkis, Bashar Safar, Christos Kontovounisios

  • July 15, 2026

Related Content

Non-bacterial cystitis following treatment with toripalimab for alpha-fetoprotein-producing gastric adenocarcinoma: a case report

E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice

Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities